2nd Hippo Pathway Targeted Drug Development Summit

Memo

It has been long understood that the Hippo pathway has clear therapeutic potential in the treatment of cancer resistance, tissue repair, and cardiac regeneration. Now, this highly attractive and targetable pathway is experiencing investment, collaboration, and interest from biopharma and academia; a once unexploited pathway is now on the brink of its first positive phase 1 clinical readout. A new frontier in precision medicine is emerging as novel data and literature forge a wider and more developed mechanistic understanding of this valuable signaling pathway. Discovery of new upstream targets to evolve the landscape of targetable nodes and therapeutic interventions, from small molecule approaches to novel modalities that target the TEAD transcription complex. The 2nd Hippo Pathway Targeted Drug Development Summit has been established as the first and only industry-led forum, focussed on progressing the functional understanding and realizing the potential of the Hippo signaling pathway to enhance the discovery, translation and clinical development of safe and effective drugs in oncology, regenerative medicine and beyond. URLs:Tickets: https://go.evvnt.com/1521706-2?pid=5569 Brochure: https://go.evvnt.com/1521706-3?pid=5569  Date and Time: On Tue, 23 May 2023 08:45 - Thu, 25 May 2023 16:45 Venue details: Boston Park Plaza, 50 Park Plaza, Boston, Massachusetts, 02116, United States Prices:Drug Developer Pricing - Conference + Workshop Day - On the Door: USD 4946.00,Drug Developer Pricing - Conference Only - On the Door: USD 2999.00,Service Provider Pricing - Conference + Workshop Day - On the Door: USD 6046.00,Service Provider Pricing - Conference Only - On the Door: USD 3799.00,Research Institutes Pricing - Conference + Workshop Day - On the Door: USD 4246.00,Research Institutes Pricing - Conference Only - On the Door: USD 2599.00 Speakers: Adeela Kamal Senior, Vice President Research and Development, SpringWorks Therapeutics, Alice Berger, Associate Professor, Fred Hutchinson Cancer Research Center (FHCRC), Alissa Guarnaccia, Postdoctoral Researcher, Genentech Inc, Bob Varelas, Professor, Boston University, Eric Holland, Senior Vice President and Director Human Biology Division, Fred Hutchinson Cancer Research Center (FHCRC), Florian Muller, Senior Director, Cancer Biology, Sporos Bioventures, James Martin, Vice Chairman and Professor, Baylor College of Medicine, Jeff Ecsedy, Chief Development Officer, Ikena Oncology, Jeno Gyuris, Chief Scientific Officer, Sporos Bioventures, Jimmy Jin, Vice President and Head of Discovery Biology, Bridge Biotherapeutics Inc., John Leach, Head of Research and Development, YAPtx, Konstantinos Konstantopoulos, Professor, Johns Hopkins University, Len Post, Chief Scientific Officer, Vivace Therapeutics Inc, Mike Bollong, Early Career Endowed Roon Chair for Cardiovascular Research, Assistant Professor, The Scripps Research Institute, Paloma Cejas, Director Early Target Biology, Exo Therapeutics, Inc, Peter Brandt, Head of Chemistry, Beactica AB, Ping Cao. Chief Executive Officer, BridGene Biosciences Inc., Satu Juhila, Project Leader, Early Clinical Development Oncology, Orion Pharma, Shaun Stauffe, Director, Center for Therapeutics Discovery, Cleveland Clinic, Srinivas Vinod Saladi, Assistant Professor, Harvard Medical School, Steen Hansen, Associate Professor, Harvard Medical School, Tinghu Zhang, Senior Medicinal Chemist, Stanford University, Xu Wu, Associate Professor, Harvard Medical School